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Abstract 
 
Visceral pain, especially in the abdominal region, represents one of the most common types of 
pain. Its chronic form is usually very hard to treat by conventional analgesic agents and 
adjuvants. We investigated the antinociceptive effect of botulinum toxin type A (BTX-A) in 
male Wistar rats in two models of visceral pain: peritonitis induced by intraperitoneal 
injection of 1% acetic acid and colitis induced by intracolonic instillation of 0.1% capsaicin. 
Pain was measured as the number of abdominal writhes. Additionally, referred mechanical 
sensitivity in the ventral abdominal area was evaluated by von Frey test and the extent of 
spinal c-Fos expression was immunohistochemically examined. BTX-A significantly reduced 
the number of abdominal writhes in both models of visceral pain after intrathecal application 
in a dose of 2 U/kg. In the experimental colitis model, BTX-A (2 U/kg) reduced both referred 
mechanical allodynia and c-Fos expression in the dorsal horn of the spinal cord (S2/S3 
segments). In contrast to intrathecal administration, BTX-A (2 U/kg) administered into the 
cisterna magna had no effect on pain suggesting that the primary site of its action is a spinal 
cord.   
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1. Introduction  
 
Botulinum toxin type A (BTX-A) inhibits neurotransmitter release due to its endopeptic 
activity against SNAP-25 (SyNaptosomal Associated Protein of 25 kDa). This enables its 
therapeutic use in disorders characterized by overactive muscles, overactive exocrine glands 
and, most recently, non-muscular pain conditions (reviewed by Dressler, 2013, Matak and 
Lacković, 2014). Antinociceptive activity of BTX-A was demonstrated in various preclinical 
(reviewed by Pavone and Luvisetto, 2010) and clinical studies (reviewed by Jabbari and 
Machado, 2011) during the last decade. It was shown that a single injection reduces pain over 
a prolonged period of time (several months), which represents the unique feature of BTX-A 
among available analgesics.  
Visceral pain, defined as pain arising from the internal organs of the body, is one of the most 
common forms of pain. In contrast to somatic pain, key features of visceral pain are diffuse 
localization typically referred to somatic sites (e.g. muscle and skin), stronger emotional and 
autonomic reactions, an unreliable association with pathology, and intense referred 
hyperalgesia (Ness, 1999, Sanoja et al., 2010). Despite of these differences, treatment has 
been the same as for somatic pain: based on non-steroidal anti-inflammatory drugs (NSAIDs), 
opioids and adjuvant analgesics like tricyclic antidepressants, antiepileptic drugs etc.  
Unlike acute forms of visceral pain, chronic visceral pain might be refractory to the listed 
drugs because of short duration of action, variable effectiveness, and unwanted side effects 
(Davis, 2012). Thus, there is a need for new therapeutic options with better effectiveness, 
longer duration of action and acceptable tolerability.   
Up to now, visceral effects of BTX-A were clinically investigated mostly in painful bladder 
and pelvic syndromes (reviewed by Russell et al., 2013, Jhang et al., 2014). In addition, a few 
case reports pointed toward the beneficial effect of BTX-A in non-cardiac chest pain 
(Maradey-Romero and Fass, 2014) and perineal pain (Lim et al., 2010). Experimentally, the 
antinociceptive effect of BTX-A was investigated only in cystitis (Chuang et al., 2004, Coelho 
et al., 2014) and prostatitis (Chuang et al., 2008). In all listed reports and studies, the 
antinociceptive effect of primarily local BTX-A injections was examined. 
Here we report that intrathecal, but not local and systemic, BTX-A application reduces pain as 
well as referred hyperalgesia and spinal c-Fos expression in experimental models of acetic 
acid induced peritonitis and capsaicin induced colitis. 
 
2. Materials and Methods 
 
2.1 Animals 
Experiments were carried out on male Wistar rats (300-400 g; University of Zagreb School of 
Medicine, Croatia). Animals were housed in a 12 h light/dark cycle with food and water 
available ad libitum, except during behavioral testing. Experiments were conducted according 
to the European Communities Council Directive (2010/63/EU). Care and handling of the 
animals were in accordance with the recommendations of the International Association for the 
Study of Pain (Zimmermann, 1983). Efforts were made to minimize the number of animals 
used. Study design, experimental protocols, and descriptions of animal treatment are closely 
followed by ARRIVE guidelines. Experiments were approved by the Ethical Committee of 
the University of Zagreb School of Medicine (permit No. 07-76/2005-43). 
 
2.2 Drugs  
The following drugs and chemicals were used: BTX-A (Botox®, Allergan, Inc., Irvine, USA); 
acetic acid (Kemika, Croatia); capsaicin (Capsaicin®, Sigma, St. Louis, MO, USA); chloral 
hydrate (Chloral hydrate®, Merck KGaA, Germany); ethanol (Kemika, Zagreb, Croatia); 
Tween 80 (Sigma, St. Louis, MO, USA); petroleum jelly (Kemig, Zagreb, Croatia).  
Each vial of Botox® contains 100 U (~4.8 ng) of purified Clostridium botulinum type A 
neurotoxin complex. To attain the needed doses, all drugs were diluted or dissolved in 0.9% 
saline, except capsaicin, which was dissolved in 0.9 % saline containing 10% Tween and 10% 
ethanol. 
Doses selected to test antinociceptive effect were chosen based on preliminary experiments 
and published data in models of somatic pain (Cui et al., 2004, Bach-Rojecky et al., 2010). 
The following chemicals were used for the immunohistochemistry: paraformaldehyde 
(Sigma-Aldrich, St. Louis, MO, USA), Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA), 
normal goat serum (Vector, Inc., Burlingame, CA, USA), c-Fos rabbit polyclonal antibody 
(Santa Cruz Biotechnology, Inc., CA, USA), goat anti-rabbit Alexa Fluor-448 (Invitrogen, 
Carlsbad, CA, USA), anti-fading agent (Fluorogel, Electron Microscopy Sciences, Hatfield, 
PA, USA). 
 
2.3 Drug administration  
Intrathecal (i.t.) injection. A small skin incision (2 cm) was performed at the lumbar L4/L5 
level. BTX-A (2 U/kg) or 0.9% saline was injected between the vertebrae in a volume of 20 µl 
and the skin was sutured; correctness of application was verified by the animal’s tail or hind 
limb brisk move.  
Intracisternal (i.c.) injection. The animals were placed in a position in which the posterior 
neck area was easy to reach. The needle was carefully advanced between the occipital 
protuberance and the spine of the atlas to the cisterna magna, and BTX-A (2 U/kg) or 0.9% 
saline was injected in a volume of 20 µl; correctness of application was verified by extraction 
of a small amount of cerebrospinal fluid (CSF).  
Intracolonic (i.col.) instillation. BTX-A (10 U/kg) or 0.9% saline in a volume of 1 mL were 
guided 7 cm proximally from the anocutaneous line, via the anus with a transparent 1 mm 
diameter cannula.  
The animals were anesthetized with i.p. injection of chloral hydrate (300 mg/kg) during the 
i.t., i.c. and i.col. administration. 
Intraperitoneal (i.p.) injection. BTX-A (15 U/kg) or 0.9% saline were injected in a volume of 
10 mL/kg to conscious, gently restrained animals. 
 
2.4 Behavioral testing 
Before testing, the animals were habituated to the testing area (plastic cage/plastic cage with a 
wire mesh floor) for 30 min. Each experimental group contained 5-6 animals. 
Acetic acid induced visceral pain model (“The writhing test”). The animals were i.p. injected 
with 10 ml/kg of 1% acetic acid and immediately returned to the transparent cage for a 1 h 
observation period, as described by Koster et al., 1959. Pain was measured as the number of 
abdominal writhes. A writhe is defined as arching of the back, extension of hind limbs and 
contraction of abdominal musculature. Measurements were conducted 5 days after i.c. and i.p. 
BTX-A or 0.9% saline injection and 2 days after the i.t. injections.  
Capsaicin induced visceral pain model. The model was originally developed for mice (Laird 
et al., 2001.), and later adapted for use in rats (Sanoja et al., 2010.). In brief, 200 µl of 0.1% 
capsaicin was administered into the colon, 7 cm proximally from the anocutaneous line, via 
the anus, with a transparent 1 mm diameter cannula. Before i.col. capsaicin instillation, 
petroleum jelly (Vaseline) was applied on the perianal area to avoid direct contact with the 
irritant. Control animals were subjected to the same treatment, but instead of capsaicin, 
received 0.9% saline. Animals injected with i.t. BTX-A or 0.9% saline were tested after 2 
days, while those i.col. instilled, after 5 days. 
Immediately after i.col. instillation of 0.1% capsaicin or 0.9% saline, the animals were 
returned to the transparent cage for a 20 min observation period where spontaneous behavior 
was observed and counted. Visceral pain behavior was considered licking and contraction of 
the abdomen, stretching, hump-backed position and hunching (Sanoja et al., 2010). After 20 
min, referred mechanical hyperalgesia was tested by using a series of von Frey ﬁlaments 
(Stoelting Co, Wood Dale, IL, USA) ranging from 1 g to 26 g, in ascending order, to the 
abdominal area with the exception of genital area. Repeated stimulation of the same area was 
avoided to prevent sensitization. The lowest ﬁlament that elicited a withdrawal response was 
considered the threshold stimulus. Each filament was applied 3 times, kept in bent position for 
2 s and with an inter-stimulus interval of 5-10 s.  
 
2.5 Immunohystochemical analysis 
An immunohystochemical analysis was performed as previously described (Drinovac et al., 
2013) on samples collected from the capsaicin induced visceral pain model. The number of c-
Fos was counted in the superficial sensory laminae of the spinal cord dorsal horn (I and II) at 
the sacral S3/S2 section.  
 
2.6 Statistical analysis 
Results, presented as mean ± S.D., were analyzed by one-way analysis of variance followed 
by the Tukey’s post hoc test. P<0.05 was considered significant. 
3. Results 
 
3.1 Intrathecal BTX-A reduces pain induced by intraperitoneal acetic acid injection 
I.p. acetic acid induced abdominal writhes, a stereotypic response pattern in a form of 
abdominal contractions, twisting and turning of the trunk, and extension of the hind limbs 
(Koster et al., 1959). BTX-A injected i.t. reduced the number of abdominal writhes (P<0.05). 
However, BTX-A application into the cisterna magna failed to affect pain induced by acetic 
acid injection (Fig. 1).  
A large volume (10 mL/kg) and dose (15 U/kg) of BTX-A administered into the peritoneal 
area had no significant antinociceptive effect on experimental peritonitis (results not shown). 
BTX-A applied in this dose caused significant muscle weakness which may have affected the 
results.  
 
3.2. Intrathecal BTX-A reduces spontaneous pain and referred hyperalgesia induced by 
intracolonic capsaicin injection  
I.col. instillation of capsaicin evoked a significant increase in visceral spontaneous pain-
related behavior during a 20 min observation period compared to i.col. instillation of saline. 
Abdominal contractions induced by saline instillation were related to the injected volume and 
colonic distention. BTX-A pretreatment did not reduce abdominal contractions induced by 
saline instillation per se (Fig. 2A). However, i.t. BTX-A pretreatment alleviated spontaneous 
pain behavior caused by capsaicin instillation (P<0.01).  
I.col. capsaicin, but not saline, produced referred secondary mechanical hyperalgesia to the 
abdomen (Fig. 2B). I.t. BTX-A pretreatment reduced the pain referred to the abdominal area 
(P<0.01).  
Local, i.col., administration of BTX-A (10 U/kg) did not affect spontaneous pain nor referred 
hyperalgesia in the colitis model as well (results not shown). 
 
3.3. Intrathecal BTX-A reduces c-Fos immunoreactivity in capsaicin induced visceral pain 
C-Fos immunoreactivity was investigated in the lumbosacral segment (L6-S2) of the spinal 
cord of rats with capsaicin-induced colitis (Fig. 3). I.t. BTX-A significantly reduced the 
number of c-Fos positive cells in the sacral S2/S3 region (P<0.05). The majority of capsaicin-
evoked c-Fos-positive neurons were located in the superficial dorsal horns (Fig. 3B).  
 
4. Discussion 
 
In contrast to different types of somatic pain (reviewed by Pavone and Luvisetto, 2010, Matak 
and Lacković, 2014) the information related to the beneficial action of BTX-A on pain arising 
from the viscera is mostly limited to the pelvic region. It was found that local BTX-A 
injections efficiently decrease pain in patients suffering from bladder pain syndrome/ 
interstitial cystitis, prostatitis and pelvic-floor muscle disorder (Abbott et al., 2006., Chung et 
al., 2012, El-Khawand et al., 2013, Gottsch et al., 2011, Kuo, 2013, Pinto et al., 2013, Smith 
et al., 2004, Zermann et al., 2000). In addition, there are isolated case reports on the beneficial 
effect of BTX-A on non-cardiac chest pain (Maradey-Romero and Fass, 2014) and perineal 
pain (Lim et al., 2010). 
Since preclinical investigations on visceral pain are sparse, limited just to rat models of 
cystitis and prostatitis (Chuang et al., 2004, 2008, 2009), the aim of the present study was to 
investigate the effect of BTX-A after its central (i.t. and i.c.) application on two 
pathophysiologically different types of visceral pain.  Central application was used because it 
was shown in behavioral studies  (Bach-Rojecky and Lacković 2005, 2009; Bach-Rojecky et 
al., 2010; Favre-Guilmard et al., 2009; Filipović et al., 2012),  and  by immunohistochemistry,  
that the antinociceptive action of BTX-A is associated with its axonal transport from the 
periphery to central sensory centers (Matak et al., 2011, 2012), in contrast to classical 
assumption that BTX-A inhibits neurotransmitter release only peripherally (Aoki, 2005). 
Although the mechanism of central BTX-A’s action is unknown, we recently demonstrated an 
interaction with spinal endogenous opioid peptides and γ-aminobutyric acid (GABA) 
(Drinovac et al., 2013, 2014). 
Accordingly, in our experiments BTX-A was injected peripherally (i.p., i.col.) or centrally 
(i.t., i.c.) to investigate the effect of BTX-A injections on spontaneous pain, referred 
hyperalgesia and neuronal activation induced by i.col. capsaicin instillation, as well as i.p. 
acetic acid induced pain behaviors. 
These two models of visceral pain mutually differ: 
1. Capsaicin induced colonic pain represents visceral pain, associated with the activation of 
visceral nociceptors (Sanoja et al., 2010), while acetic acid induced peritoneal pain is 
considered to be mixed somato-visceral pain, i.e. the somatic component cannot be excluded 
due to possible sensitization of somatic peritoneal nociceptors by acetic acid (Ness, 1999).  
2. In addition to the splanchnic and pelvic nerve, visceromotor response to i.p. acetic acid is 
mediated by the vagus nerve as well (De Groat, 1986; Sengupta, 2009).  
3. I.col. capsaicin instillation produces referred hyperalgesia, a characteristic feature of 
visceral pain, due to the convergence of somatic afferents on visceroceptive spinal neurons 
(Cervero, 2000, Traub 2003). This is not observed in acetic acid induced peritonitis.  
In the present study we showed that i.t. BTX-A injection significantly reduced acetic-acid 
induced pain behaviors (Fig. 1). To investigate whether the effect of BTX-A is restricted to the 
spinal cord, we applied the toxin into the cisterna magna, in the same volume and dose as into 
the spinal canal.  After i.c. application, BTX-A failed to affect pain induced by acetic acid, 
thus indicating that BTX-A’s antinociceptive action is predominantly of spinal origin. Since 
studies on different models of somatic pain demonstrated the antinociceptive effect of BTX-A 
after peripheral, subcutaneous application (reviewed by Pavone and Luvisetto, 2010, Matak 
and Lacković, 2014), here we investigated the effect of i.p. applied BTX-A. Injection of BTX-
A in peritoneal area also had no antinociceptive effect, but rather caused visible abdominal 
muscle weakness which made evaluation of nociceptive behavior unreliable.  
I.t. BTX-A injection in a dose as low as 2 U/kg decreases spontaneous pain as well as referred 
hyperalgesia induced by i.col. capsaicin instillation (Fig. 2). Reduction of secondary referred 
hyperalgesia cannot be explained without the assumption that BTX-A interferes with central 
sensitization at the spinal level. Local application of BTX-A (10 U/kg) into the lumen of the 
colon had no significant antinociceptive effect, even though the applied dose was five times 
higher than the i.t. dose (2 U/kg) (results not shown). The reasons might be a short retention 
of BTX-A in the colon, insufficient absorption of BTX-A, as well as an inability of BTX-A to 
enter the nerves from the lumen of the colon. The later seems likely since it was demonstrated 
that after instillation into the lumen of the bladder in guinea pigs, BTX-A does not enter the 
nerve fibers (Coelho et al., 2012). 
Visceral primary afferents, contrary to somatic primary afferents, enter the spinal cord and 
spread largely to enter multiple spinal segments above and below the segment of entry. 
Additionally, they form synaptic contacts with both superficial and deep dorsal horn neurons 
ipsilateral and contralateral to the side of entry (Sugiura and Tonosaki, 1995). The result is 
extensive, diffuse, central nervous system activation which counteracts the somatotopic 
organization that provides the precise localization of somatic stimuli. Capsaicin instillation 
into the colon induced neuronal activity in the lumbosacral spinal cord which appears to 
mediate reflex responses to acute and inflammatory colonic pain (Pitcher et al., 2013). Here, 
we showed that i.t. BTX-A significantly reduced c-Fos expression in the sacral S2/S3 
segments of the spinal cord (Fig. 3). 
An important finding of this study is the reduction of referred mechanical sensitivity by i.t. 
BTX-A in experimental colitis (Fig. 2B). The mechanism of transfer of visceral 
hypersensitivity to somatic structures is poorly understood and investigated. It is considered to 
be centrally mediated by mechanisms of central sensitization, similar to somatic pain (Gebhart 
and Bielefeldt, 2008). Recent experimental findings suggest that the development of somatic 
and visceral hyperalgesia and allodynia is paralleled by an increase in the responsiveness of 
RVM On-like cells (Rostral Ventromedial Medulla On-like cells) (Sanoja et al., 2010). This 
was demonstrated in clinics as well, in healthy volunteers (Brock et al., 2010), in patients with 
irritable bowel syndrome (Wilder-Smith and Robert-Yap, 2007) and functional dyspepsia 
(Wilder-Smith et al., 2014).  
Up until recently, data about BTX-A’s antinociceptive effect in the pelvic region were limited 
to investigating the effects of local injections on spontaneous visceral pain behavior (Chuang 
et al., 2004, 2008, 2009). In contrast to that, Coelho et al. (2014) most recently demonstrated, 
in a model of cyclophosphamide-induced cystitis, the efficacy of i.t BTX-A injections in 
reducing mechanical hypersensitivity to the abdominal and hind paw area. Together with our 
findings, these data reinforce the link between BTX-A and central sensitization, since central 
BTX-A injections were effective towards referred pain in different models of visceral pain. 
Considering that the only known target molecule for BTX-A is SNAP-25, we speculate that 
the inhibition of excitatory neurotransmitter release from the central endings of primary 
afferent terminals may be responsible for the antinociceptive action of BTX-A. Another 
possibility is that BTX-A, administered centrally, also inhibits neurotransmitter release from 
descending fibers, responsible for facilitation of pain transmission and generation of referred 
somatic and visceral hyperalgesia (Sanoja et al., 2010). Coelho et al., 2014, 
immunohistochemically found that BTX-A applied i.t. may be anterogradely transported to 
peripheral nerve endings in the urinary bladder. The transport from central site to periphery 
could also contribute to the multifaceted antinociceptive effect of BTX-A in visceral pain.  
In conclusion, the presented results provide evidence of antinociceptive effects of intrathecal 
BTX-A in experimental colitis and peritonitis, including reduction of referred hyperalgesia, 
one of the most important features of visceral pain, thus supporting predominantly central site 
of BTX-A antinociceptive action. Furthermore, these results designate BTX-A’s potential in 
treatment of patients with long lasting visceral pain.   
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Figure captions 
 
Fig. 1. I.t. BTX-A (2 U/kg) injection reduces pain behavior induced by 1% acetic acid i.p. 
injection. Mean ± S.D.; n=6; P<0.05 compared to saline (ANOVA followed by Tukey's post 
hoc) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. I.t. BTX-A (2 U/kg) pretreatment reduces: A) spontaneous pain behavior induced by 
capsaicin (0.1%) i.col. instillation. Mean ± S.D., n=6; ** P<0.01 compared to saline i.t. + 
saline i.col., BTX-A i.t. + saline i.col. and BTX-A i.t. + capsaicin i.col.; B) referred 
mechanical hyperalgesia 20 min after i.col. capsaicin instillation. Mean ± S.D., n=6; * P<0.05 
compared to saline i.t. + saline i.col. and BTX-A i.t. + saline i.col.; ** P<0.01 compared to 
saline i.t. + saline i.col., BTX-A i.t. + saline i.col. and BTX-A i.t. + capsaicin i.col. (ANOVA 
followed by Tukey's post hoc) 
 
 
 
 
 
 
Fig. 3. A) Expression of immunfluorescently labeled c-Fos (green punctate immunoreactivity) 
in the superficial laminae of the S2/S3 spinal cord sections. Representative examples of 10x 
magnification images. Scale bar: 200 µm. B) Quantitative analysis of c-Fos expression in 
laminae I and II from 10x magnification images. Total number of c-Fos positive neurons in 
superficial sensory laminae of spinal cord dorsal horn. The average number of c-Fos positive 
neurons for each animal was calculated from three spinal cord sections. Mean ± S.D., n=4; * 
P<0.01 compared to saline i.t. + capsaicin i.col. (ANOVA followed by Tukey’s post hoc) 
 
 
 
 
 
 
 
List of abbreviations: 
 
BTX-A – botulinum toxin type A 
CNS – central nervous system 
CSF – cerebrospinal fluid 
GABA – γ-aminobutyric acid 
i.c. – intracisternal 
i.col. – intracolonic 
i.p. – intraperitoneal 
i.t. – intrathecal 
NGS – normal goat serum 
NSAIDs – Non-steroidal anti-inflammatory drugs 
PBS – phosphate buffered saline 
PBST – PBS + 0.25% TritonX-100 
RVM – rostral ventromedial medulla 
SNAP-25 – SyNaptosomal Associated Protein of 25 kiloDaltons 
 
